Maurizio Chiriva-Internati, PhD, DBSc

Department of Internal Medicine, Division of Hematology & Oncology and Pulmonary and Critical Care Medicine, The Southwest Cancer Treatment and Research Center, Texas Tech University Health Sciences Center, Lubbock, Texas, USA

Dr. Chiriva-Internat is Kiromic’s Chief Executive Officer and Chief Scientific Officer. He is an Adjunct Associate Professor in the Department of Lymphoma & Multiple Myeloma at MD Anderson Cancer Center. For the past 20 years, Dr. Chiriva-Internati has investigated tumor antigens as therapeutic and diagnostic tools. His research has led to the identification of novel cancer testis antigens for the development of immunotherapeutic strategies against solid and non-solid tumors. Dr. Chiriva-Internati’s research is focused on developing new therapies for a variety of tumors, including multiple myeloma, acute myeloid leukemia, ovarian, lung, prostate, melanoma, and breast cancer. He is the author of 150 peer-reviewed publications, and is a journal reviewer for The Lancet Infectious Diseases, Cancer Research, The Journal of Immunology, International Reviews of Immunology, and Nature Reviews Clinical Oncology.